الفهرس يوجد فقط 14 صفحة متاحة للعرض العام
 |  | from | 154 |  |  |
| | | from | 154 | | |
المستخلص
Background: Preclinical studies have shown that the combination of tamoxifen and oral fluoropyrimidines in estrogen receptor (ER)-positive cell lines enhance antitumor efficacy. This prospective phase II study evaluated the safety and efficacy of combined chemo-endocrine treatment as first line in patients with metastatic breast cancer (MBC). Patients and methods: A prospective study has been conducted in NCI (National Cancer Institute) medical oncology department in outpatient setting, in the period between September 2014 and April 2016. The study included 40 patients with pathologically proven advanced breast cancer with ER +ve, Her2 -ve treated with either tamoxifen/capecitabine or letrozole/capecitabine as first line treatment for metastatic breast cancer. Thymidine phosphorylase enzyme (TP) serum level was measured before starting treatment and after one month of treatment. Serum tamoxifen, hydroxytamoxifen and 5FU levels were measured in patients receiving tamoxifen/capecitabine after one month of starting treatment. The primary end point was progression free survival (PFS), while the secondary end points were overall response rate (ORR), overall survival (OS) and incidence of adverse events as a measure of safety